HOOKIPA Pharma Inc. (HOOK)

0.8803 -0.0499 (-5.36%) At close: 04:00PM EDT

HOOKIPA Pharma Inc.

350 Fifth Avenue
72nd Floor Suite 7240
New York, NY 10118
United States
431 890 6360
https://www.hookipapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 151

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Joern Aldag	CEO & Director	848.34k	N/A	1959
Dr. Reinhard Kandera Ph.D.	CFO & Director	607.5k	N/A	1969
Prof. Rolf M. Zinkernagel M.D., Ph.D.	Co-Founder	N/A	N/A	1944
Mr. Andreas Bergthaler	Co-Founder	N/A	N/A	N/A
Mr. Lukas Flatz	Co-Founder	N/A	N/A	N/A
Dr. Roman Necina Ph.D.	Chief Operations Officer	N/A	N/A	1968
Dr. Klaus Orlinger Ph.D.	Chief Scientific Officer	N/A	N/A	1978
Mr. Matthew L. S. Beck	Executive Director of Investor Relations	N/A	N/A	N/A
Mr. Michael Szumera	Executive Director of Communications	N/A	N/A	N/A
Dr. Mark Winderlich Ph.D.	Chief Development Officer	N/A	N/A	1986

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Corporate governance

HOOKIPA Pharma Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.